<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601857</url>
  </required_header>
  <id_info>
    <org_study_id>TAS-120-203</org_study_id>
    <nct_id>NCT04601857</nct_id>
  </id_info>
  <brief_title>Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma</brief_title>
  <official_title>A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the&#xD;
      combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and&#xD;
      anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or&#xD;
      metastatic urothelial cancer who are not candidates to receive a platinum-based treatment&#xD;
      regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Objective response rate (ORR), defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) in both Cohorts A and B</measure>
    <time_frame>Approximately 8 months</time_frame>
    <description>DCR defined as the proportion of patients experiencing a best overall response of stable disease (SD), PR, or CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)in both Cohorts A and B</measure>
    <time_frame>Approximately 8 months</time_frame>
    <description>DOR defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in both Cohorts A and B</measure>
    <time_frame>Approximately 8 months</time_frame>
    <description>PFS defined as the time from the first dose of study therapy to the date of death (any cause) or disease progression, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in both Cohorts A and B</measure>
    <time_frame>Approximately 18 months</time_frame>
    <description>OS defined as the time from the date of the first dose to the death date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AE)[Safety and Tolerability]in both Cohorts A and B</measure>
    <time_frame>Approximately 8 months</time_frame>
    <description>Safety and tolerability of the futibatinib and pembolizumab combination therapy based on reported AEs, graded according to the NCI-CTCAE, Version 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Advanced and Metastatic Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>Futibatinib and Pembrolizumab (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with UC and FGFR3 mutation or FGFR1-4 fusion/rearrangement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Futibatinib and Pembrolizumab (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All other patients than in Cohort A with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Futibatinib and Pembrolizumab</intervention_name>
    <description>Patients will receive Futibatinib at an oral dose of 20 mg daily and Pembrolizumab at an intravenous dose of 200 mg every 3 weeks</description>
    <arm_group_label>Futibatinib and Pembrolizumab (Cohort A)</arm_group_label>
    <arm_group_label>Futibatinib and Pembrolizumab (Cohort B)</arm_group_label>
    <other_name>TAS120 and MK3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          2. Age ≥ 18 years of age&#xD;
&#xD;
          3. Histologically confirmed advanced or metastatic urothelial carcinoma who have not&#xD;
             received systemic treatment for advanced metastatic disease.&#xD;
&#xD;
               1. Cohort A: must have an FGFR3 mutation or FGFR1-4 fusion/rearrangement.&#xD;
&#xD;
               2. Cohort B: all other patients with UC (including patients with other FGFR or&#xD;
                  non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors)&#xD;
&#xD;
          4. Unfit for or intolerant to standard platinum-based chemotherapy.&#xD;
&#xD;
          5. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1.&#xD;
&#xD;
          6. Adequate organ function.&#xD;
&#xD;
          7. Have a measurable disease per RECIST 1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received prior therapy with anti-PD-1, anti-PD-L1/L2 agent or FGFR inhibitor.&#xD;
&#xD;
          2. History and/or current evidence of any of the following disorders:&#xD;
&#xD;
               1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is&#xD;
                  considered clinically significant in the opinion of the Investigator.&#xD;
&#xD;
               2. Ectopic mineralization/calcification considered clinically significant in the&#xD;
                  opinion of the Investigator.&#xD;
&#xD;
               3. Retinal or corneal disorder considered clinically significant in the opinion of&#xD;
                  the Investigator.&#xD;
&#xD;
          3. Has received major surgery within the previous 4 weeks.&#xD;
&#xD;
          4. Has received any non-investigational anticancer therapy within the previous 3 weeks&#xD;
             (mitomycin within the previous 5 weeks).&#xD;
&#xD;
          5. Is currently participating in a study of an investigational agent/device, or has&#xD;
             participated in a study of an investigational agent or used an investigational device&#xD;
             within 4 weeks prior to the first dose of study treatment.&#xD;
&#xD;
          6. Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
&#xD;
          7. Have an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years.&#xD;
&#xD;
          8. Have a history of (noninfectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          9. Have had an allogenic tissue/ organ transplant.&#xD;
&#xD;
         10. Has known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C&#xD;
             infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus&#xD;
             (HBV) DNA or Hepatitis C Antibody or RNA.&#xD;
&#xD;
         11. Have known active central nervous system metastases and/or carcinomatous meningitis.&#xD;
&#xD;
         12. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.&#xD;
&#xD;
         13. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maciej Gil, MD</last_name>
    <phone>1-609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vadim Koshkin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guru Sonpavde</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Hwang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Care Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Goodman Jr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Begonia Mellado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HMN Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesus García-Donás Jiménez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Gironés Sarrió</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Futibatinib</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Urothelial cancer</keyword>
  <keyword>FGFR</keyword>
  <keyword>TAS120</keyword>
  <keyword>MK3475 B04</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Futibatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

